Global Information
회사소개 | 문의 | 위시리스트

인슐린 비주사 제제

Non-injectable Insulin

리서치사 BCC Research
발행일 2020년 01월 상품 코드 923129
페이지 정보 영문 54 Pages
가격
US $ 3,950 ₩ 4,809,000 PDF by E-mail (Single User License) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄기능에 제약은 없으나 원칙적으로 허용된 인쇄횟수는 1회이며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,740 ₩ 5,771,000 PDF by E-mail (2-5 Users) help
동일 사업장 내 5명까지 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄기능에 제약은 없으나 원칙적으로 허용된 인쇄횟수는 5회까지이며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 5,688 ₩ 6,925,000 PDF by E-mail (Site License) help
동일 사업장 내 모든 분들이 공유하여 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,826 ₩ 8,311,000 PDF by E-mail (Enterprise License) help
동일 기업 내 모든 분들이 공유하여 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


인슐린 비주사 제제 Non-injectable Insulin
발행일 : 2020년 01월 페이지 정보 : 영문 54 Pages

인슐린 비주사 제제(Non-injectable Insulin) 시장에 대해 조사했으며, 성장 촉진요인 및 억제요인, 기회 및 동향 등 시장 성장에 영향을 미치는 시장 역학 분석, 형상·원료·지역별 분석, 경쟁 상황 분석 및 주요 기업 개요 등의 정보를 제공합니다.

제1장 서론

제2장 요약과 하이라이트

제3장 시장과 기술 배경

  • 시장 잠재성및 투자 분석
  • 북미는 최대 규모이자 가장 성장이 빠른 시장

제4장 시장 분석 : 형태별

  • 정제
  • 스프레이
  • 기타(필름, 추잉껌)

제5장 시장 분석 : 원료별

  • 합성 인슐린
  • 반합성 인슐린

제6장 시장 분석 : 지역별

  • 북미
  • 미국
  • 캐나다
  • 유럽
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 기타 유럽
  • 아시아태평양
  • 중국
  • 인도
  • 일본
  • 기타 아시아태평양
  • 기타 지역

제7장 경쟁 상황

제8장 기업 개요

  • ACCESS PHARMACEUTICALS INC.(ABEONA THERAPEUTICS INC.)
  • AERAMI THERAPEUTICS
  • BIOCON LTD.
  • BIODEL INC.(ALBIREO LTD.)
  • BIONOVA LIFESCIENCES
  • BOSTON THERAPEUTICS INC.
  • COROMED INC.
  • DIABETOLOGY LTD.
  • DIASOME PHARMACEUTICALS INC.
  • EMISPHERE TECHNOLOGIES INC.
  • GENEREX BIOTECHNOLOGY CORP.
  • MIDATECH PHARMA PLC
  • ORAMED PHARMACEUTICALS INC.
  • RANI THERAPEUTICS
  • SHREYA LIFE SCIENCES PVT. LTD.
LSH 20.02.13

List of Tables

  • Summary Table : Global Market for Non-injectable Insulin, by Region, Through 2024
  • Table 1 : Other Products Related to Non-injectable Insulin
  • Table 2 : Examples of Non-injectable Insulin Products
  • Table 3 : Global Market for Non-injectable Insulin, by Form, Through 2024
  • Table 4 : Global Market for Edible Insulin Pills, by Region, Through 2024
  • Table 5 : Global Market for Insulin Sprays, by Region, Through 2024
  • Table 6 : Global Market for Other Forms of Non-injectable Insulin, by Region, Through 2024
  • Table 7 : Global Market for Non-injectable Insulin, by Source, Through 2024
  • Table 8 : Global Market for Synthetic Non-injectable Insulin, by Region, Through 2024
  • Table 9 : Global Market for Semisynthetic Non-injectable Insulin, by Region, Through 2024
  • Table 10 : Global Market for Non-injectable Insulin, by Region, Through 2024
  • Table 11 : Top 10 Countries with the Highest Prevalence of Diabetes Across the Globe, 2019
  • Table 12 : North American Market for Non-injectable Insulin, by Form, Through 2024
  • Table 13 : North American Market for Non-injectable Insulin, by Source, Through 2024
  • Table 14 : Prevalence of Diabetes in North American Countries, 2010-2017
  • Table 15 : Prevalence of Diabetes in North America, 2019-2045
  • Table 16 : Prevalence of Diabetes in Europe, 2019-2045
  • Table 17 : European Market for Non-injectable Insulin, by Form, Through 2024
  • Table 18 : European Market for Non-injectable Insulin, by Source, Through 2024
  • Table 19 : Existing National Diabetes Plans in Europe, by Country
  • Table 20 : Prevalence of Diabetes in Asia-Pacific, 2019-2045
  • Table 21 : Asia-Pacific Market for Non-injectable Insulin, by Form, Through 2024
  • Table 22 : Asia-Pacific Market for Non-injectable Insulin, by Source, Through 2024
  • Table 23 : Rest of the World Market for Non-injectable Insulin, by Form, Through 2024
  • Table 24 : Rest of the World Market for Non-injectable Insulin, by Source, Through 2024

List of Figures

  • Summary Figure : Global Market for Non-injectable Insulin, by Region, 2018-2024
  • Figure 1 : Global Prevalence of Diabetes in the 20-79 Year Age Group, 2011-2045*
  • Figure 2 : Global Diabetes Prevalence, 2019-2045
  • Figure 3 : Novo Nordisk Revenue Share, by Region, 2018
  • Figure 4 : Eli Lilly Revenue Share, by Segment, 2018
  • Figure 5 : Nektar Therapeutics Revenue Share, by Region, 2018

Report Highlights:

This comprehensive report provides an in-depth assessment of the global market for non-injectable insulin. The report's key objective is to analyze areas of opportunities, key developments and the impact of this technology on industry, specifically the pharmaceutical, biotechnology and healthcare sectors. The analysis also reviews the adoption of non-injectable insulin in developed and emerging markets.

Report Scope:

The report provides a comprehensive summary of the Non-injectable insulin market, along with detailed profiles of key market players that include revenue product portfolios and recent activities. The report analyzes trends and dynamics, including drivers, limitations, challenges and opportunities. The report discusses strategies adopted by emerging market players, with recommendations for new market entrants. This research study discusses historical, current and potential market size. The report will help market players and new entrants make informed decisions about the production and export of goods and services. Organizations, distributors and exporters should find the information about market development and trends useful. The study segments the market according to applications and end uses. Geographical market analysis is provided for all major segments.

Report Includes:

  • An overview of the global market for non-injectable insulin
  • Analyses of market trends, with data from 2018, 2019, and projections of compound annual growth rates (CAGRs) through 2024
  • Information on recent major technical advances in different forms of non-injectable insulin
  • A look at the key areas of growth and adoption rate of non-injectable insulin among both commercial customers and regulatory authorities
  • Examination of strategies of the major players in the market and the impact of new technological developments

Table of Contents

Chapter 1 Introduction

  • Study Goals and Objectives
  • Reasons for Doing This Study
  • Scope of Report
  • Information Sources
  • Methodology
  • Geographic Breakdown
  • Analyst's Credentials
  • Related BCC Research Reports

Chapter 2 Summary and Highlights

Chapter 3 Market and Technology Background

  • Future Market Potential and Investment Analysis
  • North America Will be the Largest and Fastest-Growing Market

Chapter 4 Market Breakdown by Form

  • Pills
  • Spray
  • Others (Film and Chewing Gum)

Chapter 5 Market Breakdown by Source

  • Synthetic Insulin
  • Semisynthetic Insulin

Chapter 6 Market Breakdown by Region

  • North America
  • U.S.
  • Canada
  • Europe
  • U.K.
  • Germany
  • France
  • Italy
  • Spain
  • Rest of Europe
  • Asia-Pacific
  • China
  • India
  • Japan
  • Rest of Asia-Pacific
  • Rest of the World

Chapter 7 Competitive Landscape

Chapter 8 Company Profiles

  • ACCESS PHARMACEUTICALS INC. (ABEONA THERAPEUTICS INC.)
  • AERAMI THERAPEUTICS
  • BIOCON LTD.
  • BIODEL INC. (ALBIREO LTD.)
  • BIONOVA LIFESCIENCES
  • BOSTON THERAPEUTICS INC.
  • COROMED INC.
  • DIABETOLOGY LTD.
  • DIASOME PHARMACEUTICALS INC.
  • EMISPHERE TECHNOLOGIES INC.
  • GENEREX BIOTECHNOLOGY CORP.
  • MIDATECH PHARMA PLC
  • ORAMED PHARMACEUTICALS INC.
  • RANI THERAPEUTICS
  • SHREYA LIFE SCIENCES PVT. LTD.
Back to Top
전화 문의
F A Q